POSIFLEX-GROUP
24.5.2019 03:02:05 CEST | Business Wire | Press release
For the Computex 2019 show, The Posiflex Group is featuring leading solution technology from the family of brands as a fully Serviced IoT Ecosystem. Solution end points include:
- Connected Modular Kiosks, POS Terminals, and Digital Signage solutions from Posiflex and KIOSK Information Systems
- Smart Medical Displays with gesture controls from Portwell
- Connected Gaming Solutions with Player Tracking Technology from Portwell subsidiary, Ganlot
The booth display is based on common field service endpoints represented in a European Manor Destination Resort setting. Field solutions for an array of vertical market applications include QSR ordering, cinema ticketing, fashion retail customer loyalty, interactive signage, hotel / medical center check-in and bill pay, as well as casino gaming technology.
This year, in addition to their renowned POS product suite, Posiflex will be featuring newly introduced Modular Kiosk platforms (co-designed by KIOSK and Posiflex), which are configure-to-order standard models available through Global Distribution Channel. The Modular Kiosks leverage The Posiflex Group’s in-house supply chain capabilities, including self-sourced computing and peripherals like scanners, printers, and PCAP displays as well as optional transaction components common across multiple configurations and use cases – ultimately, delivering shorter lead times and reduced cost with longevity support.
Owen Chen, CEO of Posiflex notes, “Our brand family portfolio has grown to include a highly strategic blend of POS , Kiosk , and Embedded Computing Technology. This year at Computex, The Group will proudly feature the addition of a powerful Remote Management System (RMS).” This robust tool, as showcased in a Command Center, enables real-time alerting and dashboard management of any smart device within the Field Edge Network, including kiosks, POS terminals, transaction peripherals, computers, gateways, and more. This RMS solution adds actionable IoT insights to realize the best day-to-day network up-time while reducing field service costs. Mr. Chen adds, “IoT communication capabilities have profoundly elevated Field Management standards and The Posiflex Group is very pleased to offer this state-of-the-art RMS tool, coupled with its versatile Modular Kiosk offerings for the Global Channel Market.”
Real-time RMS component-level alerting puts actions in motion that prevent costly down-time. Acting on routine alerts (low-paper printer sensor / bill acceptor capacity limit sensor) stimulate daily maintenance actions that prevent outages from happening in the first place. IoT component and sensor alert monitoring provide real-time automated insights organizing Service Personnel to resolve preventative maintenance issues - while enabling customer-facing associates to focus on more pressing and profitable sales demands.
Within the Group, KIOSK Information Systems has a strong track record of providing comprehensive Field Managed Services (FMS) to an elite fleet of high-volume and mission-critical clients. This service bundle consists of:
- Remote Management System, paired with:
- Turnkey Managed Services, with knowledgeable Information Technology professionals to perform proactive remote monitoring and remediation.
- Partner-enabled Global Field Services, including Site Survey and Installation, Advanced Exchange Warranty and Field Service deployment.
KIOSK will champion the gradual global implementation of the FMS model, adding IoT and Managed Service insights across Posiflex Group’s regional service capabilities.
To learn more, please join the Team at:
Exhibition Hall: 4F, Taipei Nangang Exhibition Center Hall Two
Booth Number: R0314
About Posiflex Group:
Posiflex has designed and manufactured world-class POS solutions for more than 30 years. Since 2016, the company has acquired KIOSK and Portwell, further expanding into self-service and embedded PC offerings. The global Posiflex group is in place to provide world-class B2B Serviced IoT solutions.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190523005015/en/
Contact:
Posiflex Group Press Contact: Brad Chou, marketing@posiflex.com.tw
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release
Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom